Search Results - "Wils, J A"

Final Results of a Randomized Phase III Trial of Sequential High-Dose Methotrexate, Fluorouracil, and Doxorubicin Versus Etoposide, Leucovorin, and Fluorouracil Versus Infusional Fluorouracil and Cisplatin in Advanced Gastric Cancer: A Trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group by VANHOEFER, U, ROUGIER, P, BODENSTEIN, H, SCHMOLL, H.-J, BLEIBERG, H, NORDLINGER, B, COUVREUR, M.-L, BARON, B, WILS, J. A, WILKE, H, DUCREUX, M. P, LACAVE, A. J, VAN CUTSEM, E, PLANKER, M, DOS SANTOS, J. G, PIEDBOIS, P, PAILLOT, B

“…To compare the efficacy and tolerability of etoposide, leucovorin, and bolus fluorouracil (ELF) or infusional fluorouracil plus cisplatin (FUP) with that of…”
Get full text

Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial by Hartgrink, H.H, van de Velde, C.J.H, Putter, H, Songun, I, Tesselaar, M.E.T, Kranenbarg, E.Klein, de Vries, J.E, Wils, J.A, van der Bijl, J, van Krieken, J.H.J.M

“…Aims. Gastric cancer in Western countries is often diagnosed in an advanced stage and prognosis is poor. We performed a randomised trial with pre-operative…”
Get full text

Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy by Lalisang, R. I., Erdkamp, F. L. G., Rodenburg, C. J., Knibbeler-van Rossum, C. T. A. M., Nortier, J. W. R., van Bochove, A., Slee, P. H. Th. J., Voest, E. E., Wils, J. A., Wals, J., Loosveld, O. J. L., Smals, A. E. M., Blijham, G. H., Tjan-Heijnen, V. C. G., Schouten, H. C.

“…An increased dose-intensity can be achieved by either higher dose of chemotherapy per cycle (dose-escalation) or by shortening the interval between cycles…”
Get full text

Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group by Wils, J A, Klein, H O, Wagener, D J, Bleiberg, H, Reis, H, Korsten, F, Conroy, T, Fickers, M, Leyvraz, S, Buyse, M

“…In a prospective phase III multicenter trial, 213 patients with advanced measurable or nonmeasurable gastric cancer were randomized to receive methotrexate…”
Get more information

Epirubicin Plus Tamoxifen Versus Tamoxifen Alone in Node-Positive Postmenopausal Patients With Breast Cancer: A Randomized Trial of the International Collaborative Cancer Group by WILS, J. A, BLISS, J. M, MARTY, M, COOMBES, G, FONTAINE, C, MORVAN, F, OLMOS, T, PEREZ-LOPEZ, F. R, VASSILOPOULOS, P, WOODS, E

“…To assess whether the addition of epirubicin (EPI) therapy to prolonged treatment with tamoxifen (TAM) improves relapse-free and overall survival in…”
Get full text

Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with α-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trial by Wagener, D.J.T, Wils, J.A, Kok, T.C, Planting, A, Couvreur, M.L, Baron, B

“…A randomised phase II study of 5-fluorouracil (5-FU) plus cisplatin (CDDP) with or without α-interferon 2b was performed in patients with pancreatic cancer…”
Get full text

Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial by Songun, I, Keizer, H.J, Hermans, J, Klementschitsch, P, de Vries, J.E, Wils, J.A, van der Bijl, J, van Krieken, J.H.J.M, van de Velde, C.J.H

“…The aim of this trial was to investigate whether pre-operative chemotherapy leads to a 15% higher curative resectability rate in patients with operable gastric…”
Get full text

Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer by Lalisang, R I, Wils, J A, Nortier, H W, Burghouts, J T, Hupperets, P S, Erdkamp, F L, Schouten, H C, Blijham, G H

“…A potential application of hematopoietic growth factors is to obtain an increased dose-intensity. This can be achieved by either higher doses of chemotherapy…”
Get more information

Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer by LALISANG, R. I, VOEST, E. E, WILS, J. A, NORTIER, J. W, ERDKAMP, F. L, HILLEN, H. F, WALS, J, SCHOUTEN, H. C, BLIJHAM, G. H

“…Anthracyclines and taxanes are very effective drugs in the treatment of advanced breast cancer. With G-CSF support, the dose-intensity of this combination can…”
Get full text

Adjuvant treatment in Dukes' B and C disease by WILS, Jacques A

Get full text

Activity of cisplatin in adenocarcinoma of the pancreas by Wils, J A, Kok, T, Wagener, D J, Selleslags, J, Duez, N

“…The activity of cisplatin in metastatic adenocarcinoma of the pancreas was assessed in 33 patients. Cisplatin was administered in a dose of 100 mg/m2, every 4…”
Get more information

Prognostic significance of etiological risk factors in early breast cancer by SCHOUTEN, L. J, HUPPERETS, P. S. G. J, JAGER, J. J, VOLOVICS, L, WILS, J. A, VERBEEK, A. L. M, BLIJHAM, G. H

“…Several risk factors for the etiology of breast cancer have also been correlated with the prognosis of breast cancer. However, the published studies have…”
Get full text

Multimodality treatment of locally advanced pancreatic cancer by Wagener, D J, de Mulder, P H, Wils, J A

“…The prognosis of locally advanced pancreatic cancer is poor (median survival 3-5 months). In view of the localized character of this disease several groups…”
Get more information

Chemotherapy in pancreatic cancer: a rational pursuit? by Wils, J A

“…A review on the chemotherapy in advanced pancreatic cancer is presented. Pancreatic cancer is an extremely chemotherapy resistant tumor and results of…”
Get more information

The ‘pinch-off phenomenon’: a radiological symptom for potential fracture of an implanted permanent subclavian catheter system by Schlangen, J.Th, Debets, J.M.H., Wils, J.A.

Get full text

A randomized, double-blind, multicentre study comparing daily 2 and 5 mg of tropisetron for the control of nausea and vomiting induced by low-dose cisplatin- or non-cisplatin-containing chemotherapy by Wymenga, A. N. M., van der Graaf, W. T. A., Wils, J. A., van Heukelom, L. Siegenbeek, van der Linden, G. H. M., Dullemond-Westland, A. C., Nooy, M., van der Heul, C., de Bruijn, K. M., de Vries, E. G. E.

“…Background: This study compares efficacy, safety and tolerability of 2 and 5 mg tropisetron in prevention of nausea and vomiting induced by low-dose cisplatin-…”
Get full text

High-dose fluorouracil: a new perspective in the treatment of colorectal cancer? by Wils, J A

“…It is possible that there exists a relationship between the dose intensity of fluorouracil (5-FU) and the response in colorectal cancer. Because a very high…”
Get more information

Gastric epithelial atypia complicating hepatic arterial infusion chemotherapy by Kwee, W S, Wils, J A, Schlangen, J, Nuyens, C M, Arends, J W

“…Severe gastric lesions developed in five patients during hepatic arterial infusion chemotherapy employing 5-fluorouracil plus either leucovorin or mitomycin C…”
Get more information

Chemotherapy for gastrointestinal cancer: new hopes or new disappointments? by Wils, J A

“…Since the end of the eighties relevant progress has been made in the treatment of gastrointestinal tract cancer, as well in advanced disease as in the adjuvant…”
Get more information

Current status of chemotherapy in metastatic pancreatic cancer by Wils, J A

“…The role of chemotherapy, and especially the experience of the EORTC Gastrointestinal Group with this treatment, in advanced pancreatic cancer is discussed…”
Get more information